# PARP Inhibition for Gliomas (PI-4G or π4g)

> **NCT05297864** · PHASE2 · TERMINATED · sponsor: **University of Oklahoma** · enrollment: 15 (actual)

## Conditions studied

- Recurrent Glioblastoma
- Recurrent Astrocytoma
- Recurrent Oligodendroglioma
- Recurrent Glioma

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT05297864
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-09
- **Primary completion:** 2023-11-14
- **Final completion:** 2024-02-06
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Funder terminated funding.
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05297864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05297864, "PARP Inhibition for Gliomas (PI-4G or π4g)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05297864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*